InvestorsHub Logo
Followers 27
Posts 3416
Boards Moderated 0
Alias Born 07/17/2006

Re: Threes post# 263073

Sunday, 05/01/2016 1:24:34 PM

Sunday, May 01, 2016 1:24:34 PM

Post# of 345856
Threes, you are essentially correct. Peregrine does not have the ability to raise any more drug development money at reasonable cost, especially in view of the de-listing, reverse split box they are in.

Partnering would permit Bavi-antiPS development, if the partner will carry the bulk of the cost.

Business as usual is an insult to shareholders. If Peregrine doesn't communicate with us, taking our beating now is better than taking a complete loss later IMO.

GLTA, Paul
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News